In this issue:
- Predicting fast progression in immunotherapy-treated advanced NSCLC
- Toripalimab + axitinib vs. sunitinib as first-line treatment for advanced RCC
- Anti-PD-L1 did not reduce brain metastasis risk in extensive-stage SCLC
- Impact of BMI on survival in ICI-treated metastatic urothelial carcinoma
- Incidence of immunotherapy related hyperprogressive disease
- NZ experiences and perspectives on CAR T-cell therapy
- Avelumab, utomilumab, OX40 agonist ± RT in advanced gynaecological cancers
- Eosinophils for predicting immune-related adverse events due to ICIs
- AI-based pathology as biomarker of sensitivity to atezolizumab- bevacizumab in HCC
- No detrimental association between antibiotics and ICIs
Please login below to download this issue (PDF)